ESR1 and breast carcinoma: Although the anti-estrogen agent tamoxifen is a highly effective and commonly used treatment for patients with ER+ breast cancer 2, intrinsic and acquired tamoxifen resistance represents a major challenge for ER+ breast cancer therapy.